TolerogenixX GmbH

The object of the company is the development and marketing of the TolerogenixX process in various severe and most severe indications. It is a cell therapy procedure, innovation and unique selling point is the specific suppression of the immune reaction in the sense of an individualized immunosuppression. The result is effective immunosuppression - specifically tailored to the donor tissue - without generating the previously common general immunosuppression and the highly problematic side effects associated with it (such as increased risk of cancer). The TolerogenixX procedure involves the collection of specific donor blood cells, their treatment with mitomycin C, and their subsequent intravenous administration into the recipient. Two indications are being addressed with priority: (i) living kidney donation ("TNX"), and (ii) systemic lupus erythematosus ("SLE").